BioMarin Pharmaceutical (BMRN) stock: Winston Score, insiders and Congress trades

BioMarin Pharmaceutical is a biotechnology company that makes medicines for rare genetic diseases. Its main products include Voxzogo, a treatment for achondroplasia (a form of dwarfism), and several enzyme replacement therapies for conditions like PKU and MPS. Its customers are patients with these rare disorders, along with the hospitals and specialists who treat them. BioMarin earns money by selling its approved drugs directly to healthcare systems, hospitals, and specialty pharmacies around the world. The company operates globally, with significant revenue from the United States and Europe, and generates roughly $2–3 billion in annual sales. Its competitive moat comes from the difficulty of developing treatments for rare diseases — small patient populations and complex science create high barriers for competitors. The key growth driver is Voxzogo, which is still expanding into new markets and age groups, but the main risk is that rare disease drugs serve very small patient pools, making revenue vulnerable if a competitor or better therapy emerges.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-09.